Jordão Juliana Bahia Reis, Porto Hellen Karine Paes, Lopes Flávio Marques, Batista Aline Carvalho, Rocha Matheus Lavorenti
Laboratory of Cardiovascular Pharmacology, Faculty of Pharmacy, Federal University of Goias, Goiânia, Brazil.
Research Laboratory of Education and Pharmaceutical Services, Federal University of Goias, Goiânia, Brazil.
Planta Med. 2017 Jul;83(10):830-836. doi: 10.1055/s-0043-103281. Epub 2017 Feb 10.
Ellagic acid is described as having antioxidant and antiproliferative properties. Hence, it was hypothesized that ellagic acid could improve cardiovascular damage caused by hypertension. In this work, hypertension was induced in rats with N-Nitro-L-arginine methyl ester hydrochloride (60 mg/kg/day in drinking water) for 6 weeks. Ellagic acid was coadministered (10 or 30 mg/kg/day by gavage) between the second and sixth week. Blood pressure was recorded every week by tail-cuff plethysmography. After 6 weeks, the rats were sacrificed, the hearts and kidneys were weighed, and blood was collected. Aortas were isolated and set up to isometric recordings in an organ bath for histological assay and measuring of calcium content. Hypertension (233.6 ± 9.5 mmHg) was reduced (p < 0.01) by treatment with ellagic acid 10 or 30 mg/kg. The blood levels of nitrate/nitrite were reduced in hypertensive rats and the ellagic acid restored these levels. While the vascular relaxations to acetylcholine and sodium nitoprusside and the contraction to phenylephrine were impaired in the hypertensive group, they were improved after ellagic acid treatment. The alkaline phosphatase activity was increased by hypertension and returned to control levels after ellagic acid treatment. In the aorta, the administration of ellagic acid resulted in less aortic wall thickening and less calcification. In conclusion, ellagic acid attenuates hypertension, possibly improving nitric oxide bioavailability. The vascular response to acetylcholine, sodium nitroprusside, and phenylephrine was impaired by hypertension and improved after treatment with ellagic acid. Moreover, plasmatic alkaline phosphatase activity, calcium content, and hypertrophy in vascular tissues during hypertension were attenuated by treatment with ellagic acid.
鞣花酸被描述为具有抗氧化和抗增殖特性。因此，有人推测鞣花酸可以改善高血压引起的心血管损伤。在这项研究中，用盐酸N-硝基-L-精氨酸甲酯（饮用水中60毫克/千克/天）诱导大鼠高血压6周。在第二周和第六周之间同时给予鞣花酸（通过灌胃10或30毫克/千克/天）。每周通过尾套体积描记法记录血压。6周后，处死大鼠，称量心脏和肾脏重量，并采集血液。分离主动脉并在器官浴中进行等长记录，用于组织学分析和钙含量测量。用10或30毫克/千克的鞣花酸治疗可降低高血压（233.6±9.5毫米汞柱）（p<0.01）。高血压大鼠的硝酸盐/亚硝酸盐血水平降低，而鞣花酸可恢复这些水平。虽然高血压组对乙酰胆碱和硝普钠的血管舒张以及对去氧肾上腺素的收缩受损，但在鞣花酸治疗后有所改善。高血压会增加碱性磷酸酶活性，而鞣花酸治疗后可恢复到对照水平。在主动脉中，给予鞣花酸可减少主动脉壁增厚和钙化。总之，鞣花酸可减轻高血压，可能会提高一氧化氮的生物利用度。高血压会损害血管对乙酰胆碱、硝普钠和去氧肾上腺素的反应，而鞣花酸治疗后有所改善。此外，鞣花酸治疗可减轻高血压期间血浆碱性磷酸酶活性、钙含量和血管组织肥大。
